The abstract is read at the publisher; the summary is JClub's.
Once-weekly subcutaneous semaglutide in children aged 6 to <12 years with obesity reduced mean BMI by -13.5% at week 68 versus 2.7% with placebo.
- Why it matters: Childhood obesity has limited durable medical options, and evidence for semaglutide in younger children was missing despite approval for older age groups.
- What they did: In a phase 3 double-blind randomized trial, 167 children were assigned 2:1 to semaglutide or placebo for 104 weeks, with the primary outcome assessed at week 68.
- The result: At week 68, BMI category improved in 79% on semaglutide vs 23% on placebo (odds ratio 7.8; P<0.001), and 38% vs 2% reached below the obesity threshold.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.